ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
58,125.41
-0.19%
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs Yen
155.126
-0.38%
Brent Oil
83.955
0.50%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Lyell Immunopharma Inc (LYEL)

  7. Lyell Immunopharma Inc (LYEL) ニュース

LYEL

Lyell Immunopharma (LYEL)

Lyell Immunopharma Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:LYEL
日付受信時刻ニュースソース見出しコード企業名
2024/03/0606 : 30GlobeNewswire Inc.Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual MeetingNASDAQ:LYELLyell Immunopharma Inc
2024/02/2906 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYELLyell Immunopharma Inc
2024/02/2906 : 05GlobeNewswire Inc.Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:LYELLyell Immunopharma Inc
2024/02/2706 : 05GlobeNewswire Inc.Lyell Immunopharma Announces Participation in March Investor ConferencesNASDAQ:LYELLyell Immunopharma Inc
2024/02/1410 : 24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
2024/02/1410 : 22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
2024/02/1410 : 19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
2024/01/0406 : 05GlobeNewswire Inc.Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LYELLyell Immunopharma Inc
2023/11/2110 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
2023/11/2110 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
2023/11/2110 : 52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
2023/11/2106 : 26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYELLyell Immunopharma Inc
2023/11/1006 : 05GlobeNewswire Inc.Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of MelanomaNASDAQ:LYELLyell Immunopharma Inc
2023/11/0806 : 14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYELLyell Immunopharma Inc
2023/11/0806 : 08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYELLyell Immunopharma Inc
2023/11/0806 : 05GlobeNewswire Inc.Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023NASDAQ:LYELLyell Immunopharma Inc
2023/10/3122 : 00GlobeNewswire Inc.Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL ManufacturingNASDAQ:LYELLyell Immunopharma Inc
2023/09/2722 : 00GlobeNewswire Inc.Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:LYELLyell Immunopharma Inc
2023/09/1122 : 16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYELLyell Immunopharma Inc
2023/09/1121 : 00PR Newswire (US)Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle PlatformNASDAQ:LYELLyell Immunopharma Inc
2023/09/1121 : 00GlobeNewswire Inc.Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle PlatformNASDAQ:LYELLyell Immunopharma Inc
2023/09/0105 : 05GlobeNewswire Inc.Lyell Immunopharma to Participate in Upcoming Investor ConferencesNASDAQ:LYELLyell Immunopharma Inc
2023/08/0905 : 21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYELLyell Immunopharma Inc
2023/08/0905 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYELLyell Immunopharma Inc
2023/08/0905 : 05GlobeNewswire Inc.Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023NASDAQ:LYELLyell Immunopharma Inc
2023/07/0605 : 05GlobeNewswire Inc.Lyell Immunopharma Appoints Matthew Lang as Chief Business OfficerNASDAQ:LYELLyell Immunopharma Inc
2023/06/2205 : 55Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LYELLyell Immunopharma Inc
2023/06/2105 : 52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LYELLyell Immunopharma Inc
2023/06/2105 : 46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LYELLyell Immunopharma Inc
2023/06/2105 : 44Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LYELLyell Immunopharma Inc
 Showing the most relevant articles for your search:NASDAQ:LYEL

最近閲覧した銘柄

FX
USDGBP
US Dollar vs Sterling
AMEX
XLE
Energy Select Sector SPDR
NYSE
XOM
Exxon Mobil
NYSE
NKE
Nike
CCOM
US100
US Tech 100
CCOM
US30
US 30
AMEX
XLV
Health Care Select Sector
COIN
SOLUSD
Solana
NYSE
VZ
Verizon Communications
CCOM
US500
US 500
NASDAQ
NVDA
NVIDIA
NASDAQ
GOOGL
Alphabet
AMEX
SPY
SPDR S&P 500
NYSE
MCD
McDonalds
NASDAQ
MSFT
Microsoft
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有